Cargando…
Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880403/ http://dx.doi.org/10.1371/annotation/e57d7e73-826c-4e1c-a7c6-d2c32d3809af |
| _version_ | 1782298081906130944 |
|---|---|
| author | Foglia, Emanuela Bonfanti, Paolo Rizzardini, Giuliano Bonizzoni, Erminio Restelli, Umberto Ricci, Elena Porazzi, Emanuele Scolari, Francesca Croce, Davide |
| author_facet | Foglia, Emanuela Bonfanti, Paolo Rizzardini, Giuliano Bonizzoni, Erminio Restelli, Umberto Ricci, Elena Porazzi, Emanuele Scolari, Francesca Croce, Davide |
| author_sort | Foglia, Emanuela |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3880403 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-38804032014-01-08 Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World Foglia, Emanuela Bonfanti, Paolo Rizzardini, Giuliano Bonizzoni, Erminio Restelli, Umberto Ricci, Elena Porazzi, Emanuele Scolari, Francesca Croce, Davide PLoS One Correction Public Library of Science 2014-01-03 /pmc/articles/PMC3880403/ http://dx.doi.org/10.1371/annotation/e57d7e73-826c-4e1c-a7c6-d2c32d3809af Text en © 2014 Public Library of Science http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
| spellingShingle | Correction Foglia, Emanuela Bonfanti, Paolo Rizzardini, Giuliano Bonizzoni, Erminio Restelli, Umberto Ricci, Elena Porazzi, Emanuele Scolari, Francesca Croce, Davide Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World |
| title | Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World |
| title_full | Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World |
| title_fullStr | Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World |
| title_full_unstemmed | Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World |
| title_short | Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World |
| title_sort | correction: cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of hiv infection in italy: from randomised trial to real world |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880403/ http://dx.doi.org/10.1371/annotation/e57d7e73-826c-4e1c-a7c6-d2c32d3809af |
| work_keys_str_mv | AT fogliaemanuela correctioncostutilityanalysisoflopinavirritonavirversusatazanavirritonaviradministeredasfirstlinetherapyforthetreatmentofhivinfectioninitalyfromrandomisedtrialtorealworld AT bonfantipaolo correctioncostutilityanalysisoflopinavirritonavirversusatazanavirritonaviradministeredasfirstlinetherapyforthetreatmentofhivinfectioninitalyfromrandomisedtrialtorealworld AT rizzardinigiuliano correctioncostutilityanalysisoflopinavirritonavirversusatazanavirritonaviradministeredasfirstlinetherapyforthetreatmentofhivinfectioninitalyfromrandomisedtrialtorealworld AT bonizzonierminio correctioncostutilityanalysisoflopinavirritonavirversusatazanavirritonaviradministeredasfirstlinetherapyforthetreatmentofhivinfectioninitalyfromrandomisedtrialtorealworld AT restelliumberto correctioncostutilityanalysisoflopinavirritonavirversusatazanavirritonaviradministeredasfirstlinetherapyforthetreatmentofhivinfectioninitalyfromrandomisedtrialtorealworld AT riccielena correctioncostutilityanalysisoflopinavirritonavirversusatazanavirritonaviradministeredasfirstlinetherapyforthetreatmentofhivinfectioninitalyfromrandomisedtrialtorealworld AT porazziemanuele correctioncostutilityanalysisoflopinavirritonavirversusatazanavirritonaviradministeredasfirstlinetherapyforthetreatmentofhivinfectioninitalyfromrandomisedtrialtorealworld AT scolarifrancesca correctioncostutilityanalysisoflopinavirritonavirversusatazanavirritonaviradministeredasfirstlinetherapyforthetreatmentofhivinfectioninitalyfromrandomisedtrialtorealworld AT crocedavide correctioncostutilityanalysisoflopinavirritonavirversusatazanavirritonaviradministeredasfirstlinetherapyforthetreatmentofhivinfectioninitalyfromrandomisedtrialtorealworld |